Article
News Summary: Waters opens its newest innovation and research laboratory at University of Delaware (UD) Science, Technology and Advanced Research (STAR) campus Immerse™ Delaware brings together students, faculty, and Waters scientists with industry research partners to identify and address significant challenges facing the biopharmaceutical industry Lab opening milestone is part of multi-year Waters-UD research partnership…
Read More
Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity Robust phase 3 clinical program includes two complementary trials (ASTER and MAGNOLIA) that will enroll ~2700 patients to study abelacimab in patients with Cancer Associated Thrombosis (CAT) The ASTER study will compare abelacimab against the most widely…
Read More
Clinical program advancement represents key milestone for Aulos as a clinical-stage company and AU-007’s potential as a novel cancer treatment Excerpt from the Press Release: LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced it has dosed the first patient in a…
Read More
Three-month data from ARCT-154 booster trial show persistent neutralizing antibody activity against multiple variants of SARS-CoV-2 International pivotal Phase 3 booster trial preparations initiated with global CRO Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Please replace the graphic with the accompanying corrected graphic. The release reads: ARCTURUS REPORTS STRONG THREE-MONTH DURABILITY RESULTS FROM ARCT-154 BOOSTER…
Read More
Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs Excerpt from the Press Release: SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company…
Read More
Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels Treated eyes showed morphological and functional photoreceptor preservation EDIT-103 advancing towards IND-enabling studies Excerpt from the Press Release: CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome…
Read More
Poster selected for inclusion in conference’s Elevator Pitch Session: GDA-301 produces enhanced potency and persistence with combined genetic manipulation of CISH gene editing and the engineered expression of membrane-bound IL-15 for targeting hematologic malignancies and solid tumors GDA-601 generates promising immunotherapeutic potential to target multiple myeloma cells Company plans to select a genetically modified NK…
Read More
-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting -Results highlight potential for IRAK4 degraders to broadly impact TLR/IL-1R-driven inflammatory and autoimmune diseases in a manner superior to kinase inhibitors -Findings support further exploration of STAT3 degraders in Th17-driven autoimmune indications Excerpt from the Press Release: WATERTOWN, Mass., May 05, 2022…
Read More
Excerpt from the Press Release: RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has resumed screening and recruitment for the Phase 3 RAISE (Randomized Therapy in Status Epilepticus) trial in refractory status epilepticus (RSE). The company continues to…
Read More
Excerpt from the Press Release: NEWTOWN, Pa., May 5, 2022 /PRNewswire/ — Sen-Jam Pharmaceuticals and KVK Tech are collaborating to develop a Covid-19 oral therapy. The companies will operate in parallel while they complete the Phase II clinical trials in Nepal. KVK Tech will offer formulation and chemistry, manufacturing and controls (CMC) for the oral therapy. Furthermore, KVK…
Read More